Athira Pharma (NASDAQ:LONA) Trading Down 6.5% – Here’s What Happened
by Jessica Moore · The Cerbat GemAthira Pharma, Inc. (NASDAQ:LONA – Get Free Report)’s share price traded down 6.5% during mid-day trading on Tuesday . The stock traded as low as $9.06 and last traded at $9.07. 35,461 shares were traded during trading, a decline of 51% from the average session volume of 72,584 shares. The stock had previously closed at $9.70.
Analyst Ratings Changes
Several research firms have recently weighed in on LONA. Weiss Ratings began coverage on shares of Athira Pharma in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Thursday, February 19th. Cantor Fitzgerald began coverage on Athira Pharma in a research note on Thursday, February 26th. They set an “overweight” rating for the company. Wall Street Zen downgraded Athira Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Zacks Research raised Athira Pharma to a “hold” rating in a research note on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Analysis on LONA
Athira Pharma Stock Performance
The company has a fifty day moving average of $7.79.
Athira Pharma (NASDAQ:LONA – Get Free Report) last announced its earnings results on Thursday, March 26th. The company reported ($18.90) earnings per share (EPS) for the quarter.
Insider Activity
In related news, CEO Mark James Litton sold 5,156 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $5.37, for a total transaction of $27,687.72. Following the transaction, the chief executive officer owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. This represents a 8.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 9,110 shares of company stock valued at $48,921. 25.07% of the stock is currently owned by insiders.
Athira Pharma Company Profile
Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.
Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.